Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
Imagine...
One treatment
for mental health.
15 million cancer patients suffer from depression and anxiety in North America and Europe.
Patients need rapid access to safe and effective mental health treatments – we design and develop next-generation psychotherapeutics.
Are you an Albert Labs Investor yet?
Open Fundraising Round
CSE : ABRT
————————————————————————
We have an open financing round seeking gross proceeds of CA$3,000,000, with the first tranche (CS$500,000) offered at $0.08/Unit.
80% of our upcoming clinical trials has funding in place, including a cash rebate for an estimated CA$1.2 million from the Australian Government and a CA$830,000 strategic investment from Cantheon Capital LLC.
Our First In-Human studies on our IP protected, psilocybin-based medicine, KRN-101, are due to commence in Q3 2023 in partnership with leading Contract Research Organization, iNGENu.
————————————————————————
Value Creation from Proceeds:
Toxicology and First In-Human trials in 2023
Clinical Trial Application for its late-stage Real World Evidence trial in the United Kingdom (MHRA)
IND filing (FDA)
OTC quotation
————————————————————————
Interested in learning more?
Let’s talk.
————————————————————————
Each Unit is comprised of one common share (the “Common Share”) and one-half of one whole Common Share purchase warrant (each whole warrant, a “Warrant”) with each whole Warrant entitling the holder to purchase one additional Common Share of the Company at a price of CAD $0.12 per Share for a period of 12 months from the date of issuance. In the event that the Company’s common shares have a closing price on the CSE of greater than CAD $0.15 per common share for a period of 10 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the Company.
All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
Download
Investor Package
Meet our experts
Our people bring experience and expertise across multiple domains to deliver a scalable, effective, solution to the mental health crisis.
Mike Thompson MBE
Non-Executive Director
“The life sciences industry are well aware of the significant gap that still remains in alleviating related mental health distress”[7]
Professor Joanna Neill
Chair, Clinical Advisory Board
“Psychedelic therapy heals people. Thats really not something I’ve seen us do in psychiatry in all my career”[8]
Professor Sara Tai
Principal Investigator
“I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy and psilocybin. ”[9]
Dr Malcolm Barratt-Johnson
Chief Medical Officer
“It is an extremely exciting time for Albert Labs, we’re looking forward to treating our first patients with our product.”[10]